Addition of Pembrolizumab to SOC May Enhance HNSCC Cure Rates

Commentary
Video

For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.

In a conversation with CancerNetwork®, Douglas R. Adkins, MD, discussed what the standards of care (SOCs) were for patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC). The discussion served as context for findings from the phase 3 KEYNOTE-689 (NCT03765918) trial assessing the addition of neoadjuvant and adjuvant pembrolizumab (Keytruda) to SOC in this patient population he presented at the 2025 American Society of Clinical Oncology Annual Meeting.1

Adkins is a professor and medical oncologist in the John T. Milliken Department of Medicine of Washington University in St Louis, Missouri.

He began by contextualizing the state of head and neck cancer in the US, explaining that of the approximately 60,000 new cases every year, most patients have locally advanced disease. He remarked that the SOC for this patient group was surgery followed by radiation or chemoradiation, iterating that the cure rate for this SOC option was less than 50%.

Furthermore, he expressed that the addition of pembrolizumab to this regimen, both before and after surgery, was thought to help enhance cure rates for this patient group. He concluded by affirming that the trial supported the hypothesis, given a significantly improved major pathological response (mPR) rate, as well as event-free survival (EFS) and distant metastasis-free survival.

Results from the trial revealed that pembrolizumab extended EFS by more than 20 months, with the investigational arm (n = 363) experiencing a median EFS of 51.8 months (95% CI, 37.5-not reached [NR]) vs 30.4 months (95% CI, 21.8-50.1) with SOC alone (n = 351; HR, 0.73; 95% CI, 0.58-0.92; P = .0041). Furthermore, among patients in the respective arms, the mPRs were 9.4% and 0%, with an estimated difference of 9.3% (95% CI, 6.7%-12.8%; P < .00001).

Transcript:

For context, in the US, each year, about 60,000 new cases of head and neck cancer [occur]. Of these cases, most patients have locally advanced disease and are therefore candidates for [the current SOC for] curative therapy, typically with surgery followed by radiation with or without chemotherapy…. The chance of curing patients with the current SOC is just under 50%; there lies the problem.

[Many] patients unfortunately develop recurrence of their cancer after [SOC]. The introduction of pembrolizumab before and after surgery [with] radiation offers the opportunity to improve the chance of [curing them]. Indeed, that is what the KEYNOTE-689 trial showed.

Reference

Adkins D, Haddad RI, Tao Y, et al. Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. J Clin Oncol. 2025;43(suppl 16):6012. doi:10.1200/JCO.2025.43.16_suppl.6012

Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content